Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 1R01CA248543-01A1 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Cancer Institute (NCI) | NIH |
| Virginia Commonwealth University | OTHER |
Not provided
Not provided
Not provided
Not provided
This is a mixed-methods Hybrid Type 1 research design (efficacy study) in which we aim to conduct a two-arm randomized controlled trial and an Implementation Focused Process Evaluation of a culturally-targeted video and referral screening tool.
In this study, the investigators aim to evaluate the efficacy of a culturally targeted video previously developed by the research team vs. a Spanish-language fact sheet from an established group on enhancing genetic counseling and testing uptake and psychosocial outcomes in Latina women at risk for hereditary breast and ovarian cancer.
The investigators will test the video's efficacy while also gathering data on the implementation and future sustainability of using the Risk Screening Tool (RST) and video in community clinics.
The investigators previously developed and piloted a culturally targeted narrative video in Spanish to provide HBOC and GCT education to at-risk Latinas. The investigators expanded traditional approaches to address psychosocial barriers through risk messages designed to elicit emotional responses; emotions are often stronger predictors of behavior than cognition. Our video is responsive to Latinas' preferences, targets motivators, and addresses psychosocial barriers identified in our formative research.
In this study, the investigators aim to evaluate the efficacy of our video vs. a fact sheet from an established group on enhancing GCT uptake and psychosocial outcomes on a two-arm randomized controlled trial. The investigators will test the video's efficacy while also gathering data on the implementation and future sustainability of using an adapted Risk Screening Tool (RST) and video in community clinics.
The investigators will partner with community clinics and implement a Risk Screening Tool (RST) at their practice to identify women at risk of HBOC. Community clinic staff (N~32) will be asked to participate in a pre-implementation and a post-implementation focus group to assess implementation outcomes of integrating HBOC screening practices in their clinic. Through the community clinics, the investigators aim to recruit N~300 Latina women at risk for HBOC based on their personal or family history of cancer. Latina women at risk for HBOC will be randomized to a Video arm or Fact Sheet Arm. All participants in the randomized controlled trial will be offered genetic counseling and testing.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Video Arm | Experimental | Culturally Targeted Narrative Video: "Is My Cancer Hereditary? Rosa Visits a Genetic Counselor." Participants in the video arm will be asked to watch an 18-minute video that the research team developed and tested previously about HBOC and genetic services. The video is recorded with Spanish audio and is available with English subtitles. |
|
| Fact Sheet Arm | Active Comparator | Participants in the Fact Sheet arm will receive a Fact sheet about HBOC and genetic services and will be asked to read it in their own time. The Fact Sheet is available in English and Spanish. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Culturally Targeted Narrative Video: "Is My Cancer Hereditary? Rosa Visits a Genetic Counselor." | Behavioral | Participants randomized to the video arm will receive a link with a password by email or text message to watch the video, depending on participants' preference. Participants without internet access will receive a DVD. Participants will be instructed to watch the video alone with no interruptions. We will ask them not to share the link with others. |
| Measure | Description | Time Frame |
|---|---|---|
| Uptake of Genetic Counseling | Participants will self report whether they attended a genetic counseling session in the four months following their baseline survey. The study team will also have direct access to the genetic counseling company's records. | Change from the baseline survey to four months after baseline |
| Uptake of Genetic Testing | Participants will self report whether they completed a genetic test for hereditary cancer in the four months following their baseline survey. The study team will also have direct access to the genetic counseling company's records. | Change from the baseline survey to four months after baseline |
| Measure | Description | Time Frame |
|---|---|---|
| Knowledge about HBOC | 9-item Scale from Kasting et al, 2019. The scale has statements to which participants respond True, False, or I don't Know. The scale is scored based on the accuracy of responses. A higher score indicates higher knowledge. Scores range from 0-9. | Change from the baseline to two-week after baseline, and change from two-week follow up survey to four months after baseline |
| Measure | Description | Time Frame |
|---|---|---|
| Feasibility of the Referral Screening Tool | Qualitative measure captured through semi-structured interviews using the Consolidated Framework for Implementation Research. (e.g., What barriers and facilitators did you experience while implementing the RST?) | Change from the pre-implementation focus groups with community clinics to post implementation focus groups with community clinics (48 months) |
Inclusion Criteria:
Aim 1 and 2.
Aim 3.
Exclusion Criteria:
-
Only self-identified women will be recruited for this study
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Alejandra Hurtado de Mendoza, Ph.D | Contact | 2026878916 | ahd28@georgetown.edu |
| Name | Affiliation | Role |
|---|---|---|
| Alejandra Hurtado de Mendoza, Ph.D | Georgetown Lombardi Comprehensive Cancer Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Georgetown Lombardi Comprehensive Cancer Center | Recruiting | Washington D.C. | District of Columbia | 20007 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D061325 | Hereditary Breast and Ovarian Cancer Syndrome |
| D001943 | Breast Neoplasms |
| D010051 | Ovarian Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D004701 | Endocrine Gland Neoplasms |
| D009386 | Neoplastic Syndromes, Hereditary |
Not provided
Not provided
Hybrid Type 1 research design (efficacy study). Two arm randomized controlled trial and Implementation Focused Process Evaluation
Not provided
Not provided
Not provided
Not provided
|
| FORCE Fact Sheet | Behavioral | Participants will receive a PDF of the fact sheet by email, text message, or a printed fact sheet by mail depending on participants' preferences. The fact sheet includes information about genes, breast cancer, risk factors for HBOC, genetic counseling and testing, and resources. |
|
| Self-efficacy about attending genetic cancer risk assessment | Change in self-efficacy about genetic counseling and testing will be measured by specific items from the Theory of Planned Behavior scale (Ajzen, 2002) on a scale from 1-7 -Not at all to 7- Extremely) | Change from the baseline to two-week after baseline |
| Beliefs and Attitudes about genetic cancer risk assessment | Changes in beliefs and attitudes about genetic counseling and genetic testing. The outcome will be assessed by 22 items from a scale developed by Sussner, Jandorf, Thompson et al., 2012 in which participants respond to a Likert-type scale from 1 (completely disagree) to 7 (completely agree). | Change from the baseline to two-week after baseline |
| Subjective norms about genetic cancer risk assessment | Change in subjective norms about genetic counseling and testing will be measured by specific items from the Theory of Planned Behavior scale (Ajzen, 2002) on a scale from 1-Not at all to 7- Extremely) | Change from the baseline to two-week after baseline |
| Anticipatory emotions about genetic cancer risk assessment | Scale items on a 7-point Likert-type response (from 1-strongly disagree to 7-strongly agree). | Change from the baseline to two-week after baseline |
| Acceptability of the intervention | Overall acceptability is measured on a 4-item self-reported scale ranging from 1 to 10, where 1 = not at all to 10 = highly | At two weeks after baseline |
| Feasibility of the intervention | Proportion of women who have watched/read the video or fact sheet at the two week follow up | At two weeks after baseline |
| Acceptability of the Referral Screening Tool | Qualitative measure captured through semi-structured interviews using the Consolidated Framework for Implementation Research. | Change from the pre-implementation focus groups with community clinics to post implementation focus groups with community clinics (48 months) |
| Adoption of the Referral Screening Tool | Qualitative measure captured through semi-structured interviews using the Consolidated Framework for Implementation Research. | At the post implementation focus groups with community clinics adoption over the previous 48 months will be assessed |
| Sustainability of the Referral Screening Tool | Qualitative measure captured through semi-structured interviews using the Consolidated Framework for Implementation Research. | At the post implementation focus groups with community clinics sustainability of the screener based on their experience during the previous 48 months will be assessed |
| Virginia Commonwealth University | Recruiting | Richmond | Virginia | 23284 | United States |
|
| D010049 |
| Ovarian Diseases |
| D000291 | Adnexal Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D005833 | Genital Neoplasms, Female |
| D014565 | Urogenital Neoplasms |
| D000091662 | Genital Diseases |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D004700 | Endocrine System Diseases |
| D006058 | Gonadal Disorders |